Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of OMT-28 in Healthy Subjects
NCT03078738Phase 1Completed
- Sponsor
- OMEICOS Therapeutics
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OMT-28 in Atrial fibrillation (AFib) (7 arms), sponsored by OMEICOS Therapeutics. Primary endpoint: Frequency and nature of treatment-emergent adverse events. Started Feb 2017; status: completed.
02
Drugs
OMT-28
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03078738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078738.